Core Viewpoint - A class action lawsuit has been filed against Charming Medical Limited (NASDAQ:MCTA) for alleged fraudulent activities related to stock promotions and misinformation that led to significant stock price inflation during the class period from October 10, 2025, to November 12, 2025 [6]. Group 1: Allegations and Legal Actions - The lawsuit claims that Charming failed to disclose involvement in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals [6]. - Insiders allegedly used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [6]. - The stock price surged from an initial public offering price of $4.00 to an all-time high of $29.36 per share without any fundamental news justifying such a spike [6]. Group 2: Trading Suspension and Investor Rights - Trading of Charming's stock was halted by the SEC on November 12, 2025, due to the company's failure to provide required information to lift the suspension [6]. - Investors who purchased Charming shares during the class period and suffered losses are encouraged to contact Bragar Eagel & Squire, P.C. to discuss their legal rights and options [4][6]. Group 3: Firm Background - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in securities litigation and has a nationwide practice [5].
CHARMING MEDICAL CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Urges Charming Medical Limited Stockholders to Contact the Firm Before the February 17th Lead Plaintiff Deadline